Bolt Biotherapeutics (BOLT) Assets Average (2021 - 2026)
Bolt Biotherapeutics (BOLT) posted Assets Average of $52.4 million for Q1 2026, down 13.98% sequentially from $60.9 million in Q4 2025, and down 43.52% YoY from $92.7 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Assets Average (2021 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Assets Average for 6 years, with the latest figure at $52.4 million in Q1 2026.
- Quarterly Assets Average fell 43.52% year-over-year to $52.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.4 million (down 43.52% YoY) and the FY2025 annual result came in at $78.2 million, down 39.72% from the prior year.
- Assets Average fell to $52.4 million in Q1 2026 per BOLT's latest filing, from $60.9 million in the prior quarter.
- Over five years, Assets Average peaked at $295.3 million in Q1 2022 and troughed at $52.4 million in Q1 2026.
- A 5-year average of $158.0 million and a median of $151.3 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2026: Assets Average jumped 59.09% in 2022, then plunged 43.52% in 2026.
- Over 5 years, Assets Average stood at $236.7 million in 2022, then retreated by 29.19% to $167.6 million in 2023, then tumbled by 37.65% to $104.5 million in 2024, then slumped by 41.71% to $60.9 million in 2025, then declined by 13.98% to $52.4 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $52.4 million, $60.9 million, and $70.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | 44.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.19 Mn |
| Mar 31, 2026 | 52.39 Mn |
| Dec 31, 2025 | 60.90 Mn |
| Sep 30, 2025 | 70.28 Mn |
| Jun 30, 2025 | 80.68 Mn |
| Mar 31, 2025 | 92.75 Mn |
| Dec 31, 2024 | 104.48 Mn |
| Sep 30, 2024 | 116.76 Mn |
| Jun 30, 2024 | 133.53 Mn |
| Mar 31, 2024 | 151.34 Mn |
| Dec 31, 2023 | 167.57 Mn |
| Sep 30, 2023 | 183.03 Mn |
| Jun 30, 2023 | 198.44 Mn |
| Mar 31, 2023 | 216.99 Mn |
| Dec 31, 2022 | 236.66 Mn |
| Sep 30, 2022 | 252.87 Mn |
| Jun 30, 2022 | 271.52 Mn |
| Mar 31, 2022 | 295.26 Mn |
| Dec 31, 2021 | 320.63 Mn |
| Sep 30, 2021 | 340.31 Mn |